ArticleFuture oncology (London, England)2026

Matching-adjusted indirect comparison of enzalutamide versus apalutamide with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer.

Arun A Azad et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.